Jupiter Topco LLC Purchases Shares of 8,637,614 Revvity Inc. $RVTY

Jupiter Topco LLC acquired a new stake in Revvity Inc. (NYSE:RVTY) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 8,637,614 shares of the company’s stock, valued at approximately $961,017,000. Jupiter Topco LLC owned approximately 0.08% of Revvity as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. Ascentis Independent Advisors bought a new position in Revvity during the first quarter worth $29,000. CYBER HORNET ETFs LLC acquired a new stake in Revvity during the second quarter worth about $32,000. MUFG Securities EMEA plc acquired a new position in Revvity in the second quarter valued at approximately $34,000. SJS Investment Consulting Inc. raised its position in shares of Revvity by 5,210.0% during the 1st quarter. SJS Investment Consulting Inc. now owns 531 shares of the company’s stock worth $47,000 after purchasing an additional 521 shares during the period. Finally, Headlands Technologies LLC bought a new position in Revvity during the 2nd quarter worth $49,000. Institutional investors and hedge funds own 86.65% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on RVTY shares. Evercore reissued an “outperform” rating on shares of Revvity in a research note on Wednesday, August 5th. JPMorgan Chase & Co. cut their price target on Revvity from $96.00 to $90.00 and set a “neutral” rating on the stock in a report on Wednesday, May 6th. Sanford C. Bernstein started coverage on Revvity in a research report on Friday, June 26th. They set a “market perform” rating and a $115.00 price objective for the company. Robert W. Baird set a $117.00 price objective on Revvity in a report on Wednesday, May 6th. Finally, Wolfe Research initiated coverage on Revvity in a research note on Tuesday, June 2nd. They set a “peer perform” rating on the stock. Three investment analysts have rated the stock with a Buy rating and twelve have issued a Hold rating to the stock. According to MarketBeat, Revvity has an average rating of “Hold” and a consensus price target of $108.36.

Revvity Price Performance

Shares of NYSE:RVTY opened at $124.79 on Wednesday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.50 and a current ratio of 1.80. Revvity Inc. has a one year low of $81.22 and a one year high of $124.97. The company has a market capitalization of $13.93 billion, a PE ratio of 59.42, a price-to-earnings-growth ratio of 2.24 and a beta of 1.07. The stock has a fifty day moving average of $112.37 and a 200-day moving average of $100.63.

Revvity (NYSE:RVTY) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $1.41 earnings per share for the quarter, topping the consensus estimate of $1.21 by $0.20. Revvity had a net margin of 8.16% and a return on equity of 8.34%. The firm had revenue of $729.69 million for the quarter, compared to analysts’ expectations of $702.96 million. During the same period in the previous year, the company posted $1.18 EPS. The company’s quarterly revenue was down 1.3% compared to the same quarter last year. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, equities analysts anticipate that Revvity Inc. will post 5.36 EPS for the current fiscal year.

Revvity Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 13th. Investors of record on Friday, October 23rd will be paid a dividend of $0.07 per share. The ex-dividend date is Friday, October 23rd. This represents a $0.28 annualized dividend and a yield of 0.2%. Revvity’s dividend payout ratio is presently 13.33%.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.